These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15342012)

  • 1. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?
    Chang CC; Campoli M; Ferrone S
    Curr Opin Immunol; 2004 Oct; 16(5):644-50. PubMed ID: 15342012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?
    Rouas-Freiss N; Moreau P; Ferrone S; Carosella ED
    Cancer Res; 2005 Nov; 65(22):10139-44. PubMed ID: 16287995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.
    Ferris RL; Whiteside TL; Ferrone S
    Clin Cancer Res; 2006 Jul; 12(13):3890-5. PubMed ID: 16818683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of HLA class I and class II antigen expression and mortality in uveal melanoma.
    Ericsson C; Seregard S; Bartolazzi A; Levitskaya E; Ferrone S; Kiessling R; Larsson O
    Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2153-6. PubMed ID: 11527924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major histocompatibility antigens and antigen-processing molecules in retinoblastoma.
    Krishnakumar S; Sundaram A; Abhyankar D; Krishnamurthy V; Shanmugam MP; Gopal L; Sharma T; Biswas J
    Cancer; 2004 Mar; 100(5):1059-69. PubMed ID: 14983503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
    Ryschich E; Nötzel T; Hinz U; Autschbach F; Ferguson J; Simon I; Weitz J; Fröhlich B; Klar E; Büchler MW; Schmidt J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):498-504. PubMed ID: 15701833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.
    Raffaghello L; Nozza P; Morandi F; Camoriano M; Wang X; Garrè ML; Cama A; Basso G; Ferrone S; Gambini C; Pistoia V
    Cancer Res; 2007 Jun; 67(11):5471-8. PubMed ID: 17545629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.
    Vitale M; Pelusi G; Taroni B; Gobbi G; Micheloni C; Rezzani R; Donato F; Wang X; Ferrone S
    Clin Cancer Res; 2005 Jan; 11(1):67-72. PubMed ID: 15671529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer.
    So T; Takenoyama M; Mizukami M; Ichiki Y; Sugaya M; Hanagiri T; Sugio K; Yasumoto K
    Cancer Res; 2005 Jul; 65(13):5945-52. PubMed ID: 15994973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
    Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.
    Chang CC; Campoli M; Ferrone S
    Adv Cancer Res; 2005; 93():189-234. PubMed ID: 15797448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
    Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
    J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure, expression and function of HLA-G in renal cell carcinoma.
    Seliger B; Schlaf G
    Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-G expression in malignant melanoma.
    Rebmann V; Wagner S; Grosse-Wilde H
    Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
    Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment and immune escape.
    Ferrone S; Whiteside TL
    Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Description of HLA class I- and CD8-deficient patients: Insights into the function of cytotoxic T lymphocytes and NK cells in host defense.
    Cerundolo V; de la Salle H
    Semin Immunol; 2006 Dec; 18(6):330-6. PubMed ID: 16973375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
    Offner S; Hofmeister R; Romaniuk A; Kufer P; Baeuerle PA
    Mol Immunol; 2006 Feb; 43(6):763-71. PubMed ID: 16360021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.